Results 321 to 330 of about 254,005 (338)

Comorbidities and Healthcare Utilization in 4197 Patients With Prurigo Nodularis in Israel: A Cross‐Sectional Population‐Based Analysis

open access: yesInternational Journal of Dermatology, EarlyView.
ABSTRACT Background Prurigo nodularis patients face a significant burden of comorbidities, necessitating a comprehensive approach to care. We aimed to explore the association between prurigo nodularis, its comorbid conditions, and healthcare usage patterns.
Yuliya Valdman‐Grinshpoun   +4 more
wiley   +1 more source

Proteins and signalling pathways targeted by dapagliflozin and finerenone: Insights from DAPA‐CKD and FIGARO‐DKD

open access: yes
Diabetes, Obesity and Metabolism, EarlyView.
Mark André de la Rambelje   +4 more
wiley   +1 more source

Efficacy of luseogliflozin for renal function preservation in patients with type 2 diabetes mellitus and impaired renal function: A randomized open‐label clinical trial (RESOLUTION study)

open access: yesJournal of Diabetes Investigation, EarlyView.
Luseogliflozin alleviated renal function decline (eGFR) after an initial decrease, showing renoprotective effects in patients with renal impairment. Luseogliflozin did not increase renal events, showing safety even in patients with moderate‐to‐severe renal impairment.
Munehiro Kitada   +25 more
wiley   +1 more source

Protective association of renin‐angiotensin system inhibitor use with skeletal muscle wasting in diabetic heart failure

open access: yesJournal of Diabetes Investigation, EarlyView.
In heart failure, renin‐angiotensin system inhibitor (RASI) use was associated with less skeletal muscle wasting in patients with diabetes, but not in those without diabetes (significant interaction). The association in diabetes was more evident at lower plasma 3‐methylhistidine levels than at higher levels, suggesting a potential biomarker‐defined ...
Hidemichi Kouzu   +10 more
wiley   +1 more source

Impact of sotagliflozin on glomerular hyperfiltration in people with type 1 diabetes: A post hoc analysis of the inTandem3 trial

open access: yes
Diabetes, Obesity and Metabolism, EarlyView.
Amrit Pathak   +4 more
wiley   +1 more source

GLP‐1 Receptor Agonist Therapy and Cardiorenal Outcomes in Patients ≥ 80 Years Old With Type 2 Diabetes

open access: yesJournal of the American Geriatrics Society, EarlyView.
Effect of glucagon‐like peptide‐1 receptor agonist therapy on cardiorenal outcomes in patients aged ≥ 80 years with Type 2 diabetes. ABSTRACT Background Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) have demonstrated potential in improving glycemic control and reducing adverse outcomes in patients with Type 2 diabetes mellitus (T2DM); however ...
Jui‐Cheng Chen   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy